NCT07434414Completed
LRFN5 and OLFM4 in Bipolar Disorder
Immunoinflammatory and Synaptic Biomarkers in Bipolar Disorder: A Case-Control Study of OLFM4 and LRFN5
Source: ClinicalTrials.gov · Last updated 29 Jun 2026
Brief summary (registry, in English)
This cross-sectional observational case-control study evaluated serum levels of leucine-rich repeat and fibronectin type III domain-containing protein 5 (LRFN5) and olfactomedin-4 (OLFM4) in subjects with bipolar disorder (BD) during acute manic episodes and in healthy controls (HC). The study also assessed systemic inflammation using the Aggregate Index of Systemic Inflammation (AISI) and examined associations between biomarkers and clinical symptom severity, including Young Mania Rating Scale (YMRS) and Beck Depression Inventory (BDI) scores. The study aimed to investigate the potential interaction between synaptic dysregulation and immunoinflammatory abnormalities in BD.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 72 (actual)
- First submitted
- 20 Feb 2026
- Start date
- 7 Jul 2025
- Primary completion date
- 2 Jan 2026
- Lead sponsor
- Elazığ Mental Health and Diseases Hospital
- Diseases
- Bipolar disorder
- NCT number
- NCT07434414
What you commit to
- Study type: Observational
- Participants enrolled: 72
- From 7 Jul 2025 to the primary completion date, 2 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Alcohol/drug/substance use
- Medication-free for at least one month
- Alcohol/drug/substance use
Other illness
- Hypertension
- Diabetes mellitus
- Chronic kidney disease
- Cardiac illness
- Severe neurological disorders
- Immunological or systemic illness
- Primary psychiatric disorders other than BD
- No psychiatric diagnosis
- No systemic or immunological illness
- Hypertension
- Diabetes mellitus
- Chronic kidney disease
- Cardiac illness
- Severe neurological disorders
- Immunological or systemic illness
- Having psychiatric disorders
Age
- Age ≥ 18 years and \< 65 years
Other
- Rheumatoid arthritis
- Systemic lupus erythematosus
- For Healthy Control Group:
- \*Inclusion Criteria:
- Provided informed consent
- For Healthy Control Group:
- \*Exclusion Criteria:
- Rheumatoid arthritis
- Systemic lupus erythematosus
Criteria the registry did not label
- For Bipolar Disorder (BD) Group:
- \*Inclusion Criteria:
- Diagnosis of BD according to DSM-5-TR
- Acute manic episode
- Medication-free for at least one month prior to admission
- Age ≥ 18 years and \<65 years
- Provided informed consent
- For Bipolar Disorder (BD) Group: \*
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Elazığ Mental Health and Diseases Hospital Psychiatry Clinic Coordinator of this site? Confirm its status | Elâzığ | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.